U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative

Patent 6040446 Issued on March 21, 2000. Estimated Expiration Date: Icon_subject July 31, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Patent References

9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent
Patent #: 4355032
Issued on: 10/19/1982
Inventor: Verheyden ,   et al.

Antiviral compounds
Patent #: 5043339
Issued on: 08/27/1991
Inventor: Beauchamp

2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative Patent #: 5856481
Issued on: 01/05/1999
Inventor: Nestor, et al.

Inventors

Application

No. 127380 filed on 07/31/1998

US Classes:

544/276, Nitrogen attached directly or indirectly to the purine ring system by nonionic bonding560/106, Ring in alcohol moiety560/254Aromatic alcohol moiety

Examiners

Primary: Berch, Mark L.

Attorney, Agent or Firm

Foreign Patent References

  • 0 308 065 EP. 03/13/1985
  • 0 158 847 EP. 10/13/1985
  • 0 375 329 EP. 06/13/1990
  • 0 532 878 EP. 03/13/1993
  • 1 523 865 GB. 06/13/1978
  • 2 104 070 GB. 03/13/1983
  • 2 122 618 GB. 01/13/1984
  • 8829571 GB. 06/13/1990
  • WO 94/29311 WO. 12/13/1994

International Class

C07D 473/18

Abstract

Process and novel intermediates for preparing the L-mono-valine ester of 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol and its pharmaceutically acceptable salts. The present process and intermediates provide for reduced impurities in the mono-valine ester end-product and lower overall production costs. The process involves the condensation of a silylated guanine compound with a substituted glycerol derivative and esterification of this product with an L-valine derivative. These mono-valine products are of value as antiviral agents with improved absorption.

Other References

  • E. Jensen et al., Acta Pharm. Nord. 3(4) 243-247 (1991)
  • John C. Martin et al., J. Pharm. Sci. 76(2), p. 180-184 (1987)
  • P.C. Maudgal et al., Arch. Ophthalmol. 1984; 102: 140-142
  • Leon Colla et al.,J. Med. Chem. 98, 3, 26, 602-604 (1983)
  • L. M. Beauchamp et al., Antiviral Chemistry & Chemotherapy (1992), 3 (3), 157-16
PatentsPlus Images
Enhanced PDF formats
loading...
PatentsPlus: add to cart
PatentsPlus: add to cartSearch-enhanced full patent PDF image
$9.95more info
 
Sign InRegister
Username  
Password   
forgot password?